MCP

MCP/Drug Interactions:

  • Antilipemic agentsAntilipemic agents: Based on preliminary animal studies, pectin may lower cholesterol levels (7; 8; 9).
  • Antineoplastic agentsAntineoplastic agents: Based on animal study, MCP may significantly inhibit carbohydrate-mediated tumor growth (4; 3; 5; 2). Based on a preliminary human study, MCP may significantly decrease PSA levels in patients with prostate cancer (6).
  • Heavy metal antagonists/chelating agentsHeavy metal antagonists/chelating agents: Based on a preliminary human study, MCP may significantly increase the urinary excretion of metals (12).
  • Oral agentsOral agents: MCP may slow or reduce the absorption of oral drugs.

    • MCP/Herb/Supplement Interactions:

  • AntilipemicsAntilipemics: Based on preliminary animal studies, pectin may lower cholesterol levels (7; 8; 9).
  • AntineoplasticsAntineoplastics: Based on animal study, MCP may significantly inhibit carbohydrate-mediated tumor growth (4; 3; 5; 2). Based on a preliminary human study, MCP may significantly decrease PSA levels in patients with prostate cancer (6).
  • ChelatorsChelators: Based on a preliminary human study, MCP may significantly increase the urinary excretion of metals (12).
  • Oral agentsOral agents: MCP may slow or reduce the absorption of oral agents.

    • MCP/Food Interactions:

  • Insufficient available evidence.

    • MCP/Lab Interactions:

  • Levels of oral agentsLevels of oral agents: MCP may slow or reduce the absorption of oral agents.
  • Lipid panelLipid panel: Based on preliminary animal studies, pectin may lower cholesterol levels (7; 8).
  • PSA levelsPSA levels: Based on a preliminary human study, MCP may significantly decrease PSA levels in patients with prostate cancer (6). The effect on patients without prostate cancer is not known.
  • UrinalysisUrinalysis: Based on a preliminary human study, MCP may significantly increase the urinary excretion of metals (12).